Astrazeneca (AZN) Non Operating Income (2009 - 2026)

Astrazeneca's Non Operating Income history runs 17 years deep, the most recent figure standing at $320.0 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 220.75% year-over-year to $320.0 million; the TTM figure through Mar 2026 stood at $1.9 billion (up 1035.5% YoY), while the FY2025 annual figure was $1.3 billion, up 3.89% from the prior year.
• Non Operating Income was $320.0 million for Q1 2026 at Astrazeneca, down from $349.0 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $931.0 million in Q2 2022 to a low of -$945.0 million in Q4 2023.
• Historically, Non Operating Income has averaged $161.3 million across 5 years, with a median of $320.0 million in 2026.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income plunged 242.67% in 2022, then surged 227.37% in 2025.
• A 5-year view of Non Operating Income shows it stood at $931.0 million in 2022, then tumbled by 201.5% to -$945.0 million in 2023, then soared by 138.62% to $365.0 million in 2024, then retreated by 4.38% to $349.0 million in 2025, then slipped by 8.31% to $320.0 million in 2026.
• The last three Non Operating Income figures came in at $320.0 million (Q1 2026), $349.0 million (Q4 2025), and $349.0 million (Q3 2025), per Business Quant data.